medigraphic.com
SPANISH

Revista Cubana de Farmacia

ISSN 1561-2988 (Print)
  • Contents
  • View Archive
  • Information
    • General Information        
    • Directory
  • Publish
    • Instructions for authors        
  • medigraphic.com
    • Home
    • Journals index            
    • Register / Login
  • Mi perfil

2012, Number 3

<< Back Next >>

Rev Cubana Farm 2012; 46 (3)

Technological development of a 0.1 % sodium diclophenac formulation for opththalmological use

González CA, García PCM, Pereda RD, Bellma MA, Lagarto PA, Montes de Oca PY
Full text How to cite this article

Language: Spanish
References: 9
Page: 301-310
PDF size: 103.99 Kb.


Key words:

formulation design, stability, eye drops, sodium diclophenac.

ABSTRACT

Introduction: sodium diclophenac derives from the phenylacetic acid belonging to the non-steroid anti-inflammatories that have notable anti-rheumatic, anti-inflammatory, analgesic and antipyretic properties. It is prescribed to treat conjunctivitis, keratoconjunctivitis, corneal ulcers, corneal and conjunctival inflammation due to traumas. Additionally, it is used in reducing inflammation after the cataract surgery and in inhibiting the intraoperative myosis and the postoperative cystoid macular edema.
Objective: to design a formulation of 0.1 % sodium diclophenac eye drops that meets the quality control parameters for this pharmaceutical form and that provides the desired therapeutic effect.
Methods: five technological assays were conducted to adjust for the pH and the isotonicity of the formulation as required for an ophthalmologic preparation. Isotonicity was adjusted with boric acid, and Trometamin served to obtain highly stable pH.
Results: the technological development of the formulation was satisfactory. There was obtained a product that met all the specifications described in the manufacturer's technique for the quality control. The physical, chemical and microbiological properties of the preparation remained unchanged for 12 months under storage conditions below 25 °C.
Conclusions: the eye drop formulation, with sodium diclophenac as active principle, meets all the quality specifications for this pharmaceutical form to treat various eye diseases. This might broadens the therapeutic options in Cuba.


REFERENCES

  1. Trillo F. Tratado de Farmacia Galénica. Madrid: Luzan SA; 2000. p. 329-47; 675-717.

  2. British Pharmacopoeia. London: Printed in the United Kinston by The Stationary Office; 2004. [Versión Electrónica].

  3. Reynolds JEF. Martindale. The Complete Drug Reference. 36 ed. London: Pharmaceutical Press; 2009. p. 44-7.

  4. The Merck Index. 13 ed. New Jersey: Merck; 2001. p. 486.

  5. Rosenstein E. Diccionario de especialidades farmacéuticas. 47 ed. México, DF: Ed. PLM, SA de CV; 2001.

  6. The Unites Satated Pharmacopeial, USP 32. 30 ed. Rockville: Mack Printing; 2009. [Versión electrónica].

  7. Regulación 41/07. Validación de métodos de analíticos. Centro Estatal para el Control de Medicamentos (CECMED). La Habana, 2007. Disponible en: http://www.cecmed.sld.cu/Pages/Reg_EvalEL.htm

  8. Organisation for Economic Co-operation and Development (OECD). Guideline for testing of chemical. Acute eye irritation/corrosion. No 405. Adopted 2002. Paris: OECD; 2002.

  9. Rowe RC, Sheskly PJ, Quinn ME. Handbook of Pharmaceutical excipients. 6th ed. London: Pharmaceutical Press; 2009. p. 68, 335-6.




2020     |     www.medigraphic.com

Mi perfil

C?MO CITAR (Vancouver)

Rev Cubana Farm. 2012;46